Norwalk, Conn., December 6, 2024 – The Multiple Myeloma Research Foundation (MMRF®) today announced upcoming poster and oral presentations at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7-10 in San Diego, CA. 36 presentations will feature data from the CoMMpassSM and Immune Atlas programs, further solidifying CoMMpass as the reference dataset for advancing multiple myeloma research. The findings shed light on the biology of high-risk multiple myeloma and the tumor immune microenvironment, driving novel insights into disease stratification and treatment strategies.
“Our mission is to deliver a cure for every myeloma patient, and we know that comprehensive, scalable research initiatives are the key to achieving that goal,” said Michael Andreini, President and CEO of the MMRF. “With CoMMpass, we have generated critical insights on distinct subtypes and high-risk genetic markers of multiple myeloma, which has translated to clinical trials and research to inform efforts that can optimize treatments for all myeloma patients.”
Data from CoMMpass and the Immune Atlas programs to be highlighted at ASH include insights demonstrating the unique tumor biology and immune microenvironment of high-risk patients, including:
“CoMMpass has been a cornerstone in advancing our understanding of the complex biology of multiple myeloma for over a decade,” said Jonathan Keats, Ph.D., Assistant Professor and Director of Bioinformatics and the Collaborative Sequencing Center at TGen, as well as a senior researcher involved in CoMMpass. “Through this program, we’ve made significant strides in understanding high-risk multiple myeloma, which is associated with poorer outcomes, and are paving the way for the development of more precise and effective therapies.”
About Multiple Myeloma
Multiple myeloma is a cancer of the plasma cells that develops in bone marrow. It is the second most common blood cancer in the U.S., with 35,750 new cases and 12,590 deaths estimated to occur this year. New agents and therapies have resulted in better outcomes, but most multiple myeloma patients eventually relapse.
About CoMMpassSM
The MMRF CoMMpass study is a collaboration with clinical centers and patients with active multiple myeloma. It is one of the largest and most impactful research efforts in multiple myeloma, following over 1,100 patients across 76 centers for at least eight years. The study maps patients’ tumor genomic profile to clinical outcomes with the goal of developing a more complete understanding of both disease biology and the patient’s response to treatments. With its inclusion in more than 200 published or presented studies, CoMMpass represents the largest longitudinal genomic dataset in multiple myeloma and has led to groundbreaking discoveries that have transformed how researchers understand the biology of the disease. The MMRF continues to support the use of this resource and makes the CoMMpass data available to other researchers globally.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has raised over $600 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org.
Media Contact:
Adam Silverstein
Scient PR
[email protected]
